We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microparticles Coated with Apoptotic Antigens Blunt Autoimmune Attack

By LabMedica International staff writers
Posted on 29 Nov 2012
The molecular processes responsible for autoimmune diseases such as multiple sclerosis (MS) can be shut down by exposing cells in the immune system to microparticles coated with antigens from cells that have been reduced to fragments by apoptosis.


Investigators at Northwestern University (Chicago, IL, USA) had previously shown that antigen-bound apoptotic cells could be injected safely into patients with MS. More...
While this treatment induced T cell tolerance that prevented further autoimmune attack and slowed progression of the disease, it was not practical for routine clinical use. Senior author Dr. Stephen Miller, professor of immunology at Northwestern University, explained, "Cellular therapy is extremely expensive as it needs to be carried out in a large medical center that has the capability to isolate patient's white blood cells under sterile conditions and to re-infuse those antigen-coupled cells back into the patients. It is a costly, difficult, and time-consuming procedure."

A search for alternative methods to replace living cells as transporters of apoptotic antigens led to the development of suitable synthetic microparticles. In a paper published in the November 18, 2012, online edition of the journal Nature Biotechnology the investigators described the preparation of polystyrene or biodegradable poly(lactide-co-glycolide) microparticles coated with antigens relevant to a mouse model of MS (relapsing experimental autoimmune encephalomyelitis).

Mice with relapsing experimental autoimmune encephalomyelitis were treated by intravenous infusion of the microparticles. Results showed that treatment with the microparticles prevented the onset and modified the course of the disease. These beneficial effects required microparticle uptake by marginal zone macrophages expressing the scavenger receptor MARCO and were mediated in part by the activity of regulatory T cells, abortive T-cell activation, and T-cell anergy.

The biodegradable poly(lactide-co-glycolide) used to formulate the microparticles has already been approved by the [US] Food and Drug Administration and is currently used in sutures as well as in clinical trials to deliver anticancer agents. Dr. Miller said, "I think we have come up with a very potent way to induce tolerance that can be easily translated into clinical practice. We are doing everything we can now to take this forward."

Related Links:

Northwestern University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.